Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis

Karl E. Anderson, Douglas E. Goeger, Richard W. Carson, Shung Man K. Lee, Richard B. Stead

Research output: Contribution to journalArticle

62 Scopus citations

Abstract

Porphyria cutanea tarda, which is the most common and readily treated form of porphyria in humans, results from a deficiency of uroporphyrinogen decarboxylase in the liver.1 2 3 It is characterized by cutaneous photosensitivity. The disease is usually classified as sporadic if uroporphyrinogen decarboxylase is deficient only in the liver, and as familial (autosomal dominant) if the enzyme is also deficient in nonhepatic tissues such as erythrocytes.3 4 5 There is also a familial form in which only the hepatic enzyme is deficient.6 Increased iron content in the liver is a major contributing factor in both sporadic and familial porphyria cutanea tarda,7 as are.

Original languageEnglish (US)
Pages (from-to)315-317
Number of pages3
JournalNew England Journal of Medicine
Volume322
Issue number5
DOIs
StatePublished - Feb 1 1990

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis'. Together they form a unique fingerprint.

  • Cite this